Gilead Sciences GILD Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Total revenues by Product | ||||||
| AmBisome | $508M-0.2% | $509M+1.8% | $500M-1.4% | $507M-4.2% | $529M-0.9% | |
| Biktarvy | $14.55B+1.5% | $14.33B+1.4% | $14.14B+1.5% | $13.93B+2.2% | $13.63B+1.5% | |
| Descovy | $2.98B+8.0% | $2.76B+7.9% | $2.56B+4.7% | $2.44B+7.4% | $2.27B+7.6% | |
| Genvoya | $1.4B-6.7% | $1.5B-5.7% | $1.59B-4.3% | $1.66B-3.7% | $1.72B-2.2% | |
| Odefsey | $1.11B-5.1% | $1.17B-2.2% | $1.19B-3.9% | $1.24B-1.4% | $1.26B-2.3% | |
| Other HIV | $482M-3.6% | $500M+18.5% | $422M+2.9% | $410M+0.5% | $408M-6.0% | |
| Other Liver Disease | $827M-0.8% | $834M+22.1% | $683M+20.2% | $568M+18.3% | $480M+3.0% | |
| Other | $278M-4.1% | $290M+3.9% | $279M-3.5% | $289M-16.5% | $346M-2.8% | |
| Royalty, contract and other revenues | $487M-7.6% | $527M-2.0% | $538M+274% | $144M-8.9% | $158M+10.5% | |
| Sofosbuvir/Velpatasvir | $1.21B-4.9% | $1.27B-4.1% | $1.33B-5.4% | $1.4B-8.7% | $1.54B-3.7% | |
| Symtuza - Revenue share | $519M+4.8% | $495M-2.2% | $506M-2.9% | $521M-7.8% | $565M-4.6% | |
| Tecartus | $340M-0.9% | $343M-2.3% | $351M-4.1% | $366M-3.9% | $381M-5.5% | |
| Trodelvy | $1.51B+7.8% | $1.4B+2.1% | $1.37B+1.9% | $1.34B+3.4% | $1.3B-1.2% | |
| Veklury | $753M-17.3% | $911M-12.2% | $1.04B-28.6% | $1.45B-6.0% | $1.55B-14.1% | |
| Vemlidy | $1.06B-1.4% | $1.07B+2.6% | $1.04B+4.8% | $996M+0.9% | $987M+2.8% | |
| Yescarta | $1.44B-3.6% | $1.5B-1.4% | $1.52B-2.4% | $1.56B-1.3% | $1.58B+0.4% | |
| Total revenues by Geography | ||||||
| Europe | $5.12B+1.2% | $5.06B+1.2% | $5B+8.4% | $4.62B+1.2% | $4.56B-1.6% | |
| Rest of World | $3.48B-0.7% | $3.5B-0.4% | $3.52B+0.1% | $3.51B-1.0% | $3.55B+0.6% | |
| U.S. | $21.13B+1.2% | $20.88B+1.5% | $20.57B-0.8% | $20.74B+0.5% | $20.63B+0.2% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Gilead Sciences break its business down?
- Gilead Sciences (GILD) reports total revenues by product across 18 parts — AmBisome, Biktarvy, Descovy, Genvoya and Livdelzi. Each is extracted from the segment footnotes and tracked over time.
- Where does Gilead Sciences's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Gilead Sciences's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
